| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2468-1253(17)30142-5 |
| P698 | PubMed publication ID | 29254617 |
| P50 | author | Ian A Rowe | Q42293609 |
| P2860 | cites work | Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study | Q51541188 |
| Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. | Q53665485 | ||
| The challenge of overdiagnosis begins with its definition | Q57497922 | ||
| Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study | Q57818202 | ||
| Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury | Q68486983 | ||
| Fibrosing NASH: On Being a Blind Man in a Dark Room Looking for a Black Cat (That Isn't There) | Q82624415 | ||
| Is widespread screening for hepatitis C justified? | Q86526788 | ||
| Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study | Q24596256 | ||
| Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies | Q24658205 | ||
| Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994 | Q28384968 | ||
| Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States | Q28609429 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. | Q30234829 | ||
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis | Q30238749 | ||
| Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis | Q30448524 | ||
| Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 | ||
| Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement | Q34024860 | ||
| Overdiagnosis in cancer | Q34111655 | ||
| Antioxidant supplements to prevent mortality | Q34371902 | ||
| Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis | Q34507164 | ||
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 | ||
| Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography | Q35573240 | ||
| Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression | Q35874842 | ||
| Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 | ||
| Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States | Q36756206 | ||
| A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver | Q38105838 | ||
| Extrahepatic complications of nonalcoholic fatty liver disease | Q38134034 | ||
| Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies | Q38207382 | ||
| Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation | Q38336913 | ||
| Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation | Q38403350 | ||
| Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease | Q38559075 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease | Q38704856 | ||
| Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. | Q38985095 | ||
| Evidence for overuse of medical services around the world | Q39080255 | ||
| Drivers of poor medical care | Q39080258 | ||
| The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe | Q39471203 | ||
| Preventing overdiagnosis: how to stop harming the healthy | Q39611415 | ||
| Fatty liver is an independent predictor of early carotid atherosclerosis | Q39808935 | ||
| Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort | Q40701165 | ||
| Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors | Q41208203 | ||
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management | Q41725283 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Sick individuals and sick populations | Q43440816 | ||
| Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease | Q44475777 | ||
| No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial | Q44997998 | ||
| Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years | Q45161999 | ||
| Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland | Q45353941 | ||
| Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. | Q45917916 | ||
| Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. | Q46124754 | ||
| Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis | Q47394340 | ||
| Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States | Q48337320 | ||
| The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. | Q51343454 | ||
| P433 | issue | 1 | |
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 66-72 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | The lancet. Gastroenterology & hepatology | Q27727626 |
| P1476 | title | Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease | |
| P478 | volume | 3 |
| Q89575746 | Decision making for liver biopsy in NASH, not so FAST? |
| Q92694745 | From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis |
| Q89074070 | Non-alcoholic fatty liver disease and the interface between primary and secondary care |
| Q91264430 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies |
| Q88038376 | Paediatric NAFLD: more than just small adults |
| Q92734225 | The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information |
| Q49647324 | The painful reality of end-stage liver disease in NASH. |
Search more.